Erba Mannheim Acquires Maxmat for Diagnostics Analyzers and Advanced Development

Maxmat SA France has been renamed to Erba Diagnostics France SARL (Montpellie, France). Erba Diagnostics France will benefit the entire Erba group with its capabilities and knowhow in the field of design and development of analyzers that perform multiple functions in a laboratory spanning different segments of biochemistry, hemostasis, and immunology. Among its product-line is a revolutionary multi-analyzer that can conduct hundreds of different biochemistry, coagulation, and immunology tests on a sample.

Jaroslav Rehurek, Managing Director of Erba Lachema, said: “For us, Maxmat represents a great potential in the area of development of medical devices, and therefore it is supposed to contribute to additional growth of our company. Moreover, we are sure that its analyzers will soon find customers in our markets. Furthermore, the acquisition offers a highly favorable synergy with the current portfolio of our company.”

The acquisition will help shrink development timelines for new advanced technologies and to fulfill the needs of diagnostic laboratories. Erba Diagnostics France (formerly Maxmat SA) will also improve the group’s presence in France and French-speaking North African countries.

Mr. Suresh Vazirani, Chairman and Managing Director of Erba’s Transasia Bio-Medicals Ltd, stated, “We are excited about the new opportunities that are offered by this strategic acquisition. This acquisition will strengthen the group’s plans to emerge as a global leader in IVD.” Erba Group and Erba Diagnostics France (formerly Maxmat SA) have drawn up growth plans based on achieving economies of scale, widening product offering, creating synergy through intra-group coordination, and strengthening after-sales service support and distribution network.

Related Links:
Erba Mannheim
Erba Diagnostics France